BioNTech, Fosun Pharma eye 1B doses of COVID-19 vaccine capacity with new China JV Eli Lilly taps 3 Indian drugmakers to bolster supply of COVID-19 drug baricitinib COVID-flu combo vaccine from Novavax sparks immune response to both viruses in animals Will a waiver work? Don't expect COVID-19 vaccine patents to lift quickly, if ever, analysts say With $15B in COVID-19 vaccine sales in sight, BioNTech aspires to become a 'global immunotherapy powerhouse' Drug licenser LianBio poaches Lilly's COVID-19 antibody leader to fill CEO role Kaiser Permanente generates $2 billion profit for Q1, rebounding from 2020 loss BARDA partners with software developers to help triage COVID-19 patients COVID-19 tracker: FDA experts to discuss vaccinating kids; Behind schedule, AZ hits 50M doses delivered to the EU Featured Story | By Angus Liu As BioNTech makes inroads with its COVID-19 vaccine in Western countries under a partnership with Pfizer, the German biotech is bringing its work in China to the next level with a joint venture with licensing partner Fosun Pharma. The goal is to have manufacturing capacity of up to 1 billion doses a year. read more |
| |
|---|
|
Top Stories By Noah Higgins-Dunn Eli Lilly has tapped three Indian generic drugmakers—Cipla, Lupin and Sun Pharma—through royalty-free, non-exclusive voluntary licensing agreements to manufacture and sell its COVID-19 drug baricitinib, which recently received emergency authorization for hospitalized patients when paired with Gilead's remdesivir. read more By Arlene Weintraub As Novavax prepares to file for FDA emergency use authorization of its COVID-19 shot, the vaccine developer is already looking ahead to the possibility of combining coronavirus and flu protection. In ferrets and hamsters, a flu-COVID combo vaccine produced antibodies against both viruses at levels comparable to what was seen with either component vaccine alone, the company said. read more By Kevin Dunleavy Less than a week after the United States unveiled support for a measure that would end patent protection for COVID-19 vaccines, analysts are casting doubt on whether it will happen and if it would even make a difference. read more By Angus Liu BioNTech’s COVID-19 vaccine Comirnaty is already hauling in billions of dollars in revenue, fueling the young biotech’s aspiration to expand beyond the pandemic shot to build what its CEO Ugur Sahin calls a “global immunotherapy powerhouse.” read more By Amirah Al Idrus As LianBio strikes more deals to bring new drugs to China, the company is installing a new CEO: Yizhe Wang, Ph.D., who will arrive next Monday after leading the team that brought Eli Lilly’s COVID-19 antibody, bamlanivimab, to an emergency nod. Wang fills a vacuum left by LianBio’s founding CEO Bing Li, who departed quietly earlier this year. read more By Robert King Kaiser Permanente posted a $2 billion profit for the first quarter of the year after serving more COVID-19 patients and seeing growth in its health insurance plan. read more By Andrea Park The Biomedical Advanced Research and Development Authority has thrown its weight behind two startups analyzing COVID-19 patients’ risk of deteriorating. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The FDA's independent group of vaccine experts have scheduled a June 10 meeting to discuss the use of the COVID-19 vaccines in children, the agency said. Roughly four months behind scheduled, AstraZeneca has hit 50 million doses delivered to the European Union. And more headlines. read more |
